The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | The complex journey of CAR T-cell therapy
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the patient journey during CAR T-cell therapy, from apheresis to CAR T-cell infusion, including the manufacturing process. Prof. Mohty explains cytokine-release syndrome (CRS) and highlights the need for a close follow-up and monitoring after treatment. Even though CAR T-cell therapy journey is long, the results are promising and bring hope to patients with relapsed/refractory diseases.
